within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M05B_DrugsAffectingBoneStructureAndMineralization.M05BX01_Ipriflavone;

model Ipriflavone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.17,
    Cl = 5e-06,
    adminDuration = 600,
    adminMass = 600 / 1000000,
    adminCount = 1,
    Vd = 0.03,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0008333333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ipriflavone</td></tr><tr><td>ATC code:</td><td>M05BX01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>600</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>30</td><td>L</td></tr>
    <tr><td>clearance:</td><td>18</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ipriflavone is a synthetic isoflavone derivative previously investigated for the treatment and prevention of osteoporosis and bone loss. It acts by inhibiting bone resorption and stimulating bone formation. The drug is not currently approved for therapeutic use in the USA or Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adult subjects after oral administration, based on published reviews and available limited pharmacokinetic studies.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M05BX01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ipriflavone;
